WALTHAM, Mass.--(BUSINESS WIRE)--Dynogen Pharmaceuticals, Inc. announced today that it has been awarded United States Patent No. 7,115,606, which claims the use of DDP225 for the treatment of overactive bladder (OAB) in patients who are not incontinent. This newly issued patent represents Dynogen’s third U.S. patent for DDP225 and its second U.S. patent for DDP225 in the genitourinary disorders field. U.S. Patent No. 6,846,823, which was awarded to Dynogen in January of 2005, covers the use of DDP225 for the treatment of specific lower urinary tract disorder symptoms, such as urinary frequency, urinary urgency and nocturia (the disturbance of nighttime sleep because of the need to urinate).
